Review



humanized single-chain variable fragment (scfv) antibody  (ProMab Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    ProMab Inc humanized single-chain variable fragment (scfv) antibody
    Humanized Single Chain Variable Fragment (Scfv) Antibody, supplied by ProMab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/10__1038_slash_d43747___021___00026___w-66-28-25?v=ProMab+Inc
    Average 90 stars, based on 1 article reviews
    humanized single-chain variable fragment (scfv) antibody - by Bioz Stars, 2026-08
    90/100 stars

    Images



    Similar Products

    86
    Creative Biolabs anti human efnb2 single chain variable fragment scfv b11
    Anti Human Efnb2 Single Chain Variable Fragment Scfv B11, supplied by Creative Biolabs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/10__1158_slash_0008___5472__can___23___1950-107-7-15?v=Creative+Biolabs
    Average 86 stars, based on 1 article reviews
    anti human efnb2 single chain variable fragment scfv b11 - by Bioz Stars, 2026-08
    86/100 stars
      Buy from Supplier

    90
    ProMab Inc humanized single-chain variable fragment (scfv) antibody
    Humanized Single Chain Variable Fragment (Scfv) Antibody, supplied by ProMab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/10__1038_slash_d43747___021___00026___w-66-28-25?v=ProMab+Inc
    Average 90 stars, based on 1 article reviews
    humanized single-chain variable fragment (scfv) antibody - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    IONTAS Ltd human single-chain variable fragment (scfv) antibody phage library
    Binding and neutralizing capability of the <t>scFv</t> clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.
    Human Single Chain Variable Fragment (Scfv) Antibody Phage Library, supplied by IONTAS Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/pmc07329857-49-2-1?v=IONTAS+Ltd
    Average 90 stars, based on 1 article reviews
    human single-chain variable fragment (scfv) antibody phage library - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    Eureka Therapeutics human single-chain variable fragment (scfv) phage library antibody
    Binding and neutralizing capability of the <t>scFv</t> clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.
    Human Single Chain Variable Fragment (Scfv) Phage Library Antibody, supplied by Eureka Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/pmc04738012-273-13-11?v=Eureka+Therapeutics
    Average 90 stars, based on 1 article reviews
    human single-chain variable fragment (scfv) phage library antibody - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    99
    Danaher Inc human recombinant single chain fragment variable scfv antibodies
    Binding and neutralizing capability of the <t>scFv</t> clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.
    Human Recombinant Single Chain Fragment Variable Scfv Antibodies, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/pm24763547-43-17-74?v=Danaher+Inc
    Average 99 stars, based on 1 article reviews
    human recombinant single chain fragment variable scfv antibodies - by Bioz Stars, 2026-08
    99/100 stars
      Buy from Supplier

    90
    BioInvent human recombinant single-chain fragment variable (scfv) antibodies
    Binding and neutralizing capability of the <t>scFv</t> clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.
    Human Recombinant Single Chain Fragment Variable (Scfv) Antibodies, supplied by BioInvent, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/pm24063262-16-68-86?v=BioInvent
    Average 90 stars, based on 1 article reviews
    human recombinant single-chain fragment variable (scfv) antibodies - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    90
    BioInvent human recombinant single-chain fragment variable (scfv) antibody fragments
    Binding and neutralizing capability of the <t>scFv</t> clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.
    Human Recombinant Single Chain Fragment Variable (Scfv) Antibody Fragments, supplied by BioInvent, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/humanized+single-chain+variable+fragment+%28scfv%29+antibody/pmc03098590-76-3-48?v=BioInvent
    Average 90 stars, based on 1 article reviews
    human recombinant single-chain fragment variable (scfv) antibody fragments - by Bioz Stars, 2026-08
    90/100 stars
      Buy from Supplier

    Image Search Results


    Binding and neutralizing capability of the scFv clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.

    Journal: Scientific Reports

    Article Title: An in vitro methodology for discovering broadly-neutralizing monoclonal antibodies

    doi: 10.1038/s41598-020-67654-7

    Figure Lengend Snippet: Binding and neutralizing capability of the scFv clones discovered using phage display and a cross-panning strategy against CTxs from African cobras. ( a ) In direct ELISA, 113 cross-binding scFv clones recognized both Nn 18 and Nn 20 venom fractions. Fraction 8 from Dendroaspis polylepis venom (Dp 8, Dendrotoxin 1) was used as a negative control. ( b ) Seven of the unique cross-binding scFv clones bound five different CTxs-containing fractions from three different cobra species (Nn 18, Nn 20, Nn 25, Nmo 13, and Nm 17). Bars represent mean ± SD of triplicate wells. ( c ) Different amounts of venom fractions (2–80 µg/mL) were added to N/TERT cells. After 24 h of incubation at 37 °C, cell viability was determined by quantifying the ATP release into the culture media, and mean cell survival percentage was calculated from triplicate wells. The half-maximal inhibitory concentration (IC 50 ) was determined by fitting the mean cell survival percentage of inhibition-concentration data into a Hill equation and has been represented as values ± standard error. ( d ) Neutralization of the cytolytic effects of the venom fractions on human N/TERT cells by the discovered broadly-neutralizing TPL0027_01_F7 scFv antibody. 2 IC 50 of the venom fractions were pre-incubated with TPL0027_01_F7. The scFv antibody TPL0039_05_E2, targeting the unrelated Myotoxin II from Bothrops asper venom, was used as a negative control. Experiments were performed in triplicates, and results are expressed as mean ± SD. One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was performed for each group, except the Nn 18 group, and p < 0.05 was considered to be of statistical significance. For the Nn 18 group, a one-way ANOVA could not be carried out because the group only contained two samples, therefore, an unpaired t test was carried out with p < 0.05 considered to be of statistical significance. For each of the five fractions, there was a statistically significant difference between “fraction + TPL0027_01_F7” and “fraction”. For the four groups containing the “fraction + TPL0035_09_E2”, there was a statistically significant difference between this and “fraction + TPL0027_01_F7”. However, differences between “fraction” and “fraction + TPL0035_09_E2” were not statistically significant for any of the four groups. *Insufficient amounts, this fraction was not available for testing.

    Article Snippet: The IONTAS human single-chain variable fragment (scFv) antibody phage library containing a clonal diversity of 4 × 10 10 was employed for phage display selections.

    Techniques: Binding Assay, Clone Assay, Direct ELISA, Negative Control, Combined Bisulfite Restriction Analysis Assay, Incubation, Concentration Assay, Inhibition, Neutralization